Breaking News Instant updates and real-time market news.

2020-05-01 07:13:54 GLYC GlycoMimetics $2.80 / -0.1 (-3.45%) 07:13 05/01/20 05/01 07:13 05/01/20 07:13	GlycoMimetics reports Q1 EPS (18c), consensus (30c) Reports Q1 revenue $9,000 vs. no revenue last year. As of March 31, GlycoMimetics had cash and cash equivalents of $ 154.8M as compared to $158.2M as of December 31, 2019. "During the quarter, patient enrollment continued on track in GlycoMimetics' Phase 3 registration program evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) as well as in our collaboration with the National Cancer Institute (NCI) on a multi-center clinical trial evaluating the drug candidate in newly diagnosed patients fit for chemotherapy. Enrollment slowed in April as a result of the COVID-19 pandemic, and we continue to actively monitor the situation. At this time it is too early for us to comment on the potential impact of the pandemic on completion of enrollment in either trial, or the potential impact on cash burn. In addition, we are working closely with Apollomics in the Greater China region to initiate the Apollomics-funded third registration trial for uproleselan," commented Rachel King, CEO.	01 May 22 May
GLYC GlycoMimetics $2.80 / -0.1 (-3.45%) 02/11/20 Roth Capital GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital 12/10/19 Roth Capital GlycoMimetics' uproleselan presentation 'very exciting,' says Roth Capital 11/21/19 Roth Capital GlycoMimetics price target lowered to $9 from $12 at Roth Capital 11/21/19 Stifel GlycoMimetics' delayed Phase 3 timeline doesn't impact LT thesis, says Stifel

2020-05-01 07:13:54

GLYC

GlycoMimetics

$2.80 / -0.1 (-3.45%)

07:13

05/01/20

05/01

07:13

05/01/20

07:13

GlycoMimetics reports Q1 EPS (18c), consensus (30c)

Reports Q1 revenue $9,000 vs. no revenue last year. As of March 31, GlycoMimetics had cash and cash equivalents of $ 154.8M as compared to $158.2M as of December 31, 2019. "During the quarter, patient enrollment continued on track in GlycoMimetics' Phase 3 registration program evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) as well as in our collaboration with the National Cancer Institute (NCI) on a multi-center clinical trial evaluating the drug candidate in newly diagnosed patients fit for chemotherapy. Enrollment slowed in April as a result of the COVID-19 pandemic, and we continue to actively monitor the situation. At this time it is too early for us to comment on the potential impact of the pandemic on completion of enrollment in either trial, or the potential impact on cash burn. In addition, we are working closely with Apollomics in the Greater China region to initiate the Apollomics-funded third registration trial for uproleselan," commented Rachel King, CEO.

01
May
22
May

GLYC GlycoMimetics

$2.80 / -0.1 (-3.45%)

02/11/20 Roth Capital: GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital

12/10/19 Roth Capital: GlycoMimetics' uproleselan presentation 'very exciting,' says Roth Capital

11/21/19 Roth Capital: GlycoMimetics price target lowered to $9 from $12 at Roth Capital

11/21/19 Stifel: GlycoMimetics' delayed Phase 3 timeline doesn't impact LT thesis, says Stifel

TODAY'S FREE FLY STORIES

Downgrade	Associated British Foods downgraded to Sell from Neutral at Redburn » 06:17 03/03/21 03/03 06:17 03/03/21 06:17 ASBFY Associated British Foods $0.00 / + (+0.00%) Redburn analyst Emily… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research ASBFY Associated British Foods $0.00 / + (+0.00%) 05:11 Today Redburn Associated British Foods downgraded to Sell from Neutral at Redburn 02/26/21 Barclays Associated British Foods price target raised to 2,700 GBp from 2,600 GBp at Barclays 02/23/21 Grupo Santander Associated British Foods upgraded to Buy from Hold at Grupo Santander 01/21/21 Berenberg Associated British Foods price target raised to 2,650 GBp at Berenberg
Hot Stocks	Patterson-UTI reports an average of 69 drilling rigs operating in February » 06:17 03/03/21 03/03 06:17 03/03/21 06:17 PTEN Patterson-UTI $7.57 / -0.305 (-3.87%) Patterson-UTI reported… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PTEN Patterson-UTI $7.57 / -0.305 (-3.87%) 02/03/21 Patterson-UTI reported average of 67 drilling rigs operating for January 01/06/21 Patterson-UTI reports an average of 64 drilling rigs operating in December 12/03/20 Patterson-UTI reports an average of 61 drilling rigs operating in November 11/04/20 Patterson-UTI reports an average of 61 drilling rigs operating in October PTEN Patterson-UTI $7.57 / -0.305 (-3.87%) 12/15/20 Citi Patterson-UTI price target raised to $6 from $3 at Citi 11/30/20 Susquehanna Susquehanna raises targets across Oilfield Services on cyclical rebound 07/16/20 Scotiabank Patterson-UTI downgraded to Underperform from Sector Perform at Scotiabank 05/28/20 Citi Patterson-UTI price target raised to $4.50 from $1.90 at Citi PTEN Patterson-UTI $7.57 / -0.305 (-3.87%) 02/04/21 Patterson-UTI reports Q4 EPS (57c), consensus (62c) 10/22/20 Patterson-UTI reports Q3 EPS (60c), consensus (62c)
Hot Stocks	U.S. District Court rules in AstraZeneca's favor in Symbicort patent litigation » 06:17 03/03/21 03/03 06:17 03/03/21 06:17 AZN AstraZeneca $47.72 / -0.38 (-0.79%) , MMM 3M $177.16 / +0.78 (+0.44%) , VTRS Viatris $14.28 / -0.46 (-3.12%) The company states:… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AZN MMM VTRS AZN AstraZeneca $47.72 / -0.38 (-0.79%) 03/02/21 AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX 03/01/21 FibroGen, AstraZeneca report FDA to hold AdCom meeting to review roxadustat NDA 02/26/21 Amgen, AstraZeneca report 'positive' results from NAVIGATOR Phase 3 trial 02/24/21 ChemoCentryx appoints Tausif Butt as EVP, COO MMM 3M $177.16 / +0.78 (+0.44%) 02/23/21 3M and Pegatron join to develop Virtual Reality headset 02/18/21 Stanley Black & Decker elects Jane Palmieri, Mojdeh Poul to board 02/16/21 3M to invest $1B over next 20 years to achieve carbon neutrality 02/16/21 Rockwell Automation appoints Nicholas Gangestad as CFO VTRS Viatris $14.28 / -0.46 (-3.12%) 02/22/21 Viatris to initiate 11c per share quarterly dividend in May 01/28/21 FTC approves final order on Pfizer, Mylan deal with conditions 12/21/20 Mapi Pharma provides enrollment update on Phase III GA Depot trial 12/18/20 Viatris acquires 27,736 common shares AZN MMM VTRS AZN AstraZeneca $47.72 / -0.38 (-0.79%) 02/25/21 Fly Intel: Top five analyst upgrades 02/25/21 UBS AstraZeneca upgraded to Buy from Neutral at UBS 02/04/21 Piper Sandler Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler 02/01/21 BofA BofA downgrades Moderna to Underperform, sees shares priced for 'best-case' MMM 3M $177.16 / +0.78 (+0.44%) 02/03/21 Fly Intel: Top five analyst upgrades 02/03/21 Argus 3M upgraded to Buy from Hold at Argus 02/03/21 Argus 3M upgraded to Buy from Hold at Argus 01/27/21 Credit Suisse 3M price target lowered to $197 from $208 at Credit Suisse VTRS Viatris $14.28 / -0.46 (-3.12%) 03/02/21 JPMorgan Viatris downgraded to Neutral on 'modest' growth at JPMorgan 03/02/21 JPMorgan Viatris downgraded to Neutral from Overweight at JPMorgan 02/26/21 Wolfe Research Viatris downgraded to Peer Perform from Outperform at Wolfe Research 02/23/21 Barclays Viatris price target lowered to $20 from $26 at Barclays AZN MMM VTRS AZN AstraZeneca $47.72 / -0.38 (-0.79%) 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year MMM 3M $177.16 / +0.78 (+0.44%) 01/26/21 3M sees FY21 EPS $9.20-$9.70, consensus $9.52 01/26/21 3M reports Q4 adjusted EPS $2.38, consensus $2.15 01/25/21 Notable companies reporting before tomorrow's open 01/25/21 Notable companies reporting before tomorrow's open VTRS Viatris $14.28 / -0.46 (-3.12%) 02/22/21 Viatris sees FY21 revenue $17.2B-$17.8B, consensus $18.46B AZN MMM AZN AstraZeneca $47.72 / -0.38 (-0.79%) 02/28/21 AstraZeneca sells stake in Moderna for over $1B, The Times reports 02/25/21 Johnson & Johnson one-dose COVID-19 vaccine approved by Bahrain, Reuters says 02/24/21 Germany to receive 16M AstraZeneca Covid vaccines in Q2, Reuters reports 02/23/21 AstraZeneca: COVID-19 vaccine could receive U.S. EUA by April, Reuters says MMM 3M $177.16 / +0.78 (+0.44%) 02/11/21 3M helping law enforcement stop sale of counterfeit N95 masks, CNBC reports 01/16/21 3M stock 'unloved, underpriced,' Barron's says 09/22/20 3M exploring possible sale of food safety division, Bloomberg says 09/22/20 3M exploring possible sale of food safety division, Bloomberg says AZN MMM AZN AstraZeneca $47.72 / -0.38 (-0.79%) 02/16/21 Fly Intel: Wall Street's top stories for Tuesday 02/16/21 Fly Intel: Wall Street's top stories at midday 02/08/21 Fly Intel: Wall Street's top stories for Monday 02/08/21 Fly Intel: Wall Street's top stories at midday MMM 3M $177.16 / +0.78 (+0.44%) 01/26/21 Fly Intel: Wall Street's top stories for Tuesday 01/26/21 Fly Intel: Wall Street's top stories at midday 01/26/21 Fly Intel: Pre-market Movers 12/14/20 Fly Intel: Pre-market Movers 03/20/21 PDUFA Date for Roxadustat--Extended Date 05/06/21 FARXIGA Granted Priority Review for Chronic Kidney Disease AZN MMM VTRS AZN AstraZeneca $47.72 / -0.38 (-0.79%) 02/24/21 AstraZeneca call volume above normal and directionally bullish 02/17/21 AstraZeneca call volume above normal and directionally bullish 12/30/20 Unusually active option classes on open December 30th 12/29/20 Unusually active option classes on open December 29th MMM 3M $177.16 / +0.78 (+0.44%) 01/26/21 Unusually active option classes on open January 26th VTRS Viatris $14.28 / -0.46 (-3.12%) 03/02/21 Viatris put volume heavy and directionally bearish 02/19/21 Viatris call volume above normal and directionally bullish 02/08/21 Viatris put volume heavy and directionally bearish 01/14/21 Viatris call volume above normal and directionally bullish
Recommendations	Veeva price target raised to $350 from $340 at Piper Sandler » 06:16 03/03/21 03/03 06:16 03/03/21 06:16 VEEV Veeva $288.36 / -5.21 (-1.77%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly VEEV Veeva $288.36 / -5.21 (-1.77%) 01/14/21 Veeva to become public benefit corporation on February 1 01/13/21 Veeva 'becomes first public company to convert to a public benefit corporation' 01/13/21 Veeva shareholders vote to convert to public benefit corporation 11/17/20 Veeva announces Bristol-Myers adoption of Vault PromoMats VEEV Veeva $288.36 / -5.21 (-1.77%) 02/17/21 KeyBanc Veeva price target raised to $353 from $332 at KeyBanc 01/13/21 Citi Elastic price target raised to $190 from $160 at Citi 01/11/21 Piper Sandler Veeva price target raised to $340 from $310 at Piper Sandler 01/11/21 Piper Sandler Bill.com price target raised to $140 from $120 at Piper Sandler VEEV Veeva $288.36 / -5.21 (-1.77%) 03/02/21 Veeva sees FY22 adjusted EPS $3.20, consensus $3.11 03/02/21 Veeva sees Q1 adjusted EPS 77c-78c, consensus 74c 03/02/21 Veeva reports Q4 adjusted EPS 78c, consensus 68c 12/01/20 Veeva sees FY22 revenue $1.7B-$1.72B, consensus $1.7B VEEV Veeva $288.36 / -5.21 (-1.77%) 01/13/21 Citi says sell Palantir on deceleration in growth, upcoming lockup expiry 12/01/20 Fly Intel: After-Hours Movers 10/14/20 Microsoft resumption, Nio upgrade among top calls on Wall Street
Earnings	AES Corp. backs FY21 adjusted EPS view $1.50-$1.58, consensus $1.56 » 06:15 03/03/21 03/03 06:15 03/03/21 06:15 AES AES Corp. $26.82 / -0.18 (-0.67%) Sees FY21 parent free… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options AES AES Corp. $26.82 / -0.18 (-0.67%) 02/05/21 AES subsidiary IPL to acquire solar project in Clinton County 01/04/21 AES Corp. to sell Mong Duong 2 coal-fired plant in Vietnam 12/07/20 AES Corp. raises quarterly dividend by 5% to 15.05c per share 11/17/20 AES and AIMCo sign agreement for merger plan AES AES Corp. $26.82 / -0.18 (-0.67%) 01/11/21 BofA BofA US 1 List changes 09/18/20 Morgan Stanley AES Corp. price target raised to $23.50 from $19 at Morgan Stanley 08/13/20 BofA AES Corp. added to US 1 List; Ameren removed at BofA 05/20/20 Seaport Global Seaport Global starts power and competitive retail sector with positive outlook AES AES Corp. $26.82 / -0.18 (-0.67%) 02/25/21 AES Corp. sees FY21 adjusted EPS $1.50-1.58, consensus $1.56 02/25/21 AES Corp. reports Q4 EPS 47c, consensus 44c 11/06/20 AES Corp. reaffirms 7%-9% average annual growth target through 2022 11/06/20 AES Corp. backs FY20 adjusted EPS view $1.32 -$1.42, consensus $1.37 09:00 Today AES Corporation AES AES Corp. $26.82 / -0.18 (-0.67%) 11/20/20 AES Corp. call volume above normal and directionally bullish 10/15/20 AES Corp. call volume above normal and directionally bullish 09/24/20 AES Corp. call volume above normal and directionally bullish

Recommendations	ChampionX price target raised to $18 from $12.25 at Piper Sandler » 06:15 03/03/21 03/03 06:15 03/03/21 06:15 CHX ChampionX $21.86 / -0.94 (-4.12%) Piper Sandler analyst Ian… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CHX ChampionX $21.86 / -0.94 (-4.12%) 01/19/21 ChampionX CFO Jayy Nutt to retire, Kenneth Fisher to succeed 12/21/20 ChampionX to transfer stock exchange listing to Nasdaq 11/16/20 ChampionX, Modumetal announce collaboration agreement CHX ChampionX $21.86 / -0.94 (-4.12%) 02/26/21 Barclays ChampionX price target raised to $29 from $23 at Barclays 02/25/21 Wells Fargo ChampionX price target raised to $24 from $19 at Wells Fargo 01/11/21 Barclays ChampionX price target raised to EUR 23 from EUR 19 at Barclays 12/21/20 Goldman Sachs ChampionX initiated with a Buy at Goldman Sachs CHX ChampionX $21.86 / -0.94 (-4.12%) 02/23/21 ChampionX reports Q4 EPS 7c, consensus 6c 10/28/20 ChampionX reports Q3 adjusted EPS 3c, consensus (4c)
Recommendations	Adidas price target lowered to EUR 284 from EUR 292 at Piper Sandler » 06:14 03/03/21 03/03 06:14 03/03/21 06:14 ADDYY Adidas $0.00 / + (+0.00%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly ADDYY Adidas $0.00 / + (+0.00%) 02/17/21 Adidas starts divestiture process for Reebok 12/14/20 Adidas assessing strategic alternatives for Reebok, including potential sale 09/24/20 Kanye West demands Gap board seat before product releases 09/10/20 Kohl's launches Adidas active collection with actress Zoe Saldana ADDYY Adidas $0.00 / + (+0.00%) 02/26/21 RBC Capital Adidas price target raised to EUR 300 from EUR 290 at RBC Capital 02/23/21 Credit Suisse Adidas upgraded to Neutral from Underperform at Credit Suisse 02/11/21 UBS Adidas upgraded to Buy from Neutral at UBS 02/01/21 Deutsche Bank Adidas price target raised to EUR 250 from EUR 240 at Deutsche Bank ADDYY Adidas $0.00 / + (+0.00%) 12/29/20 Reebok's $2.4B price tag brings new buyers to the table, Forbes reports 10/22/20 Adidas said to plan to sell Reebok business, Reuters reports ADDYY Adidas $0.00 / + (+0.00%) 10/06/20 Beyond Meat boosted by Piper Sandler teen survey results 09/22/20 Fly Intel: What to watch in Nike's earnings report
Periodicals	Some Catholic bishops advise against certain Covid-19 vaccines, WSJ reports » 06:14 03/03/21 03/03 06:14 03/03/21 06:14 JNJ Johnson & Johnson $159.01 / -0.32 (-0.20%) , MRNA Moderna $146.61 / -10.81 (-6.87%) , PFE Pfizer $33.51 / -0.185 (-0.55%) At least two Catholic… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options JNJ MRNA PFE JNJ Johnson & Johnson $159.01 / -0.32 (-0.20%) 03/02/21 Merck to help produce Johnson & Johnson COVID-19 vaccine 02/28/21 Fly Intel: Top five weekend stock stories 02/28/21 CDC Advisory Committee recommends J&J single-shot COVID vaccine for adults 18+ 02/27/21 Johnson & Johnson Covid vaccine granted emergency approval from FDA MRNA Moderna $146.61 / -10.81 (-6.87%) 02/25/21 Moderna's chief medical officer Tal Zaks to leave company in late September 02/24/21 Moderna makes new capital investment to boost manufacturing capacity 02/24/21 Moderna ships mRNA-1273.351 to NIH for clinical study 02/24/21 Takeda provides update on Novavax, Moderna COVID-19 vaccine candidates in Japan PFE Pfizer $33.51 / -0.185 (-0.55%) 03/02/21 Strata Oncology starts trial with Pfizer as partner 03/01/21 Flowserve supports Pfizer in production of COVID-19 vaccine 02/26/21 Pfizer: EMA accepts MAA for 20-valent pneumococcal conjugate vaccine candidate 02/26/21 Pfizer, Opko Health: EMA accepts marketing application for somatrogon JNJ MRNA PFE JNJ Johnson & Johnson $159.01 / -0.32 (-0.20%) 02/10/21 BTIG Model N upgraded to Buy from Neutral at BTIG 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 02/01/21 Wells Fargo Moderna price target raised to $145 from $129 at Wells Fargo 02/01/21 BofA BofA downgrades Moderna to Underperform, sees shares priced for 'best-case' MRNA Moderna $146.61 / -10.81 (-6.87%) 03/01/21 Chardan Moderna price target raised to $182 from $107 at Chardan 02/26/21 Barclays Moderna price target raised to $178 from $169 at Barclays 02/26/21 Brookline Moderna price target raised to $205 from $180 at Brookline 02/25/21 Piper Sandler Moderna transitioning into profitable company, says Piper Sandler PFE Pfizer $33.51 / -0.185 (-0.55%) 02/23/21 B. Riley Securities B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance 02/10/21 KeyBanc Maravai Lifesciences price target raised to $39 from $33 at KeyBanc 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/03/21 Mizuho Pfizer price target lowered to $42 from $44 at Mizuho JNJ MRNA PFE JNJ Johnson & Johnson $159.01 / -0.32 (-0.20%) 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 01/25/21 Notable companies reporting before tomorrow's open 01/25/21 Notable companies reporting before tomorrow's open MRNA Moderna $146.61 / -10.81 (-6.87%) 02/25/21 Moderna reports Q4 EPS (69c), consensus (35c) 02/24/21 Notable companies reporting before tomorrow's open 02/24/21 Notable companies reporting before tomorrow's open 10/29/20 Moderna reports Q3 EPS (59c), consensus (43c) PFE Pfizer $33.51 / -0.185 (-0.55%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open 19 May JNJ MRNA PFE JNJ Johnson & Johnson $159.01 / -0.32 (-0.20%) 03/02/21 IPG Mediabrands planning event focused on Black-owned media firms, AdAge says 03/02/21 Merck to help produce J&J Covid vaccine, Washington Post reports 03/02/21 Johnson & Johnson Covid-19 vaccine shipments begin rollout, WSJ reports 02/26/21 FDA panel says J&J COVID-19 vaccine benefits outweigh risks, CNBC says MRNA Moderna $146.61 / -10.81 (-6.87%) 02/28/21 AstraZeneca sells stake in Moderna for over $1B, The Times reports 02/17/21 Moderna to supply EU with another 150M vaccine doses in 2021, FT reports 02/12/21 FDA tells Moderna it can boost vaccine supply in each vial, NY Times reports 02/11/21 White House secures deals for additional 200M COVID-19 vaccine doses, CNBC says PFE Pfizer $33.51 / -0.185 (-0.55%) 02/25/21 Johnson & Johnson one-dose COVID-19 vaccine approved by Bahrain, Reuters says 02/19/21 Pfizer to use additional capacity to boost vaccine output, Bloomberg says 02/19/21 BioNTech, Pfizer vaccine 85% effective after first dose, FT reports 02/17/21 Moderna to supply EU with another 150M vaccine doses in 2021, FT reports JNJ MRNA PFE JNJ Johnson & Johnson $159.01 / -0.32 (-0.20%) 03/02/21 Fly Intel: Wall Street's top stories for Tuesday 03/02/21 Fly Intel: Wall Street's top stories at midday 03/01/21 Fly Intel: Wall Street's top stories for Monday 03/01/21 Fly Intel: Wall Street's top stories at midday MRNA Moderna $146.61 / -10.81 (-6.87%) 02/25/21 Fly Intel: Pre-market Movers 02/24/21 Fly Intel: After-Hours Movers 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday PFE Pfizer $33.51 / -0.185 (-0.55%) 02/19/21 Fly Intel: Wall Street's top stories for Friday 02/19/21 Fly Intel: Wall Street's top stories at midday 02/18/21 Fly Intel: Wall Street's top stories for Thursday 02/18/21 Fly Intel: Wall Street's top stories at midday 03/05/21 Medical Technology 03/08/21 Biopharmaceuticals 03/02/21 41st Annual Healthcare Virtual Conference 03/16/21 31st Annual Healthcare Virtual Conference 04/20/21 Johnson & Johnson - JNJ 03/24/21 Arthritis Advisory Committee and Drug Safety & Risk Mgmt Committee Meeting 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 03/05/21 Pfizer JNJ MRNA PFE JNJ Johnson & Johnson $159.01 / -0.32 (-0.20%) 03/01/21 Unusually active option classes on open March 1st 01/26/21 Early notable gainers among liquid option names on January 26th 12/01/20 Johnson & Johnson call volume above normal and directionally bullish 10/13/20 Unusually active option classes on open October 13th MRNA Moderna $146.61 / -10.81 (-6.87%) 03/01/21 Moderna call volume above normal and directionally bullish 02/01/21 Moderna call volume above normal and directionally bullish 01/25/21 Moderna call volume above normal and directionally bullish 12/17/20 Moderna call volume above normal and directionally bullish PFE Pfizer $33.51 / -0.185 (-0.55%) 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th
Recommendations	I-MAB price target raised to $75 from $55 at H.C. Wainwright » 06:12 03/03/21 03/03 06:12 03/03/21 06:12 IMAB I-MAB $59.12 / -4.98 (-7.77%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly IMAB I-MAB $59.12 / -4.98 (-7.77%) 02/25/21 I-MAB doses first patient in China Phase 3 growth hormone deficiency study 02/10/21 I-MAB's Phase 1 study of cancer candidate cleared by China's NMPA 02/05/21 I-Mab reports clinical advancements of antibody uliledlimab in China and U.S. 02/04/21 I-MAB says first patient dosed in Phase 2 clinical study of TJ107 IMAB I-MAB $59.12 / -4.98 (-7.77%) 02/25/21 Fly Intel: Top five analyst initiations 02/25/21 Piper Sandler I-MAB initiated with an Overweight at Piper Sandler 12/07/20 H.C. Wainwright I-MAB initiated with a Buy at H.C. Wainwright 09/08/20 Cantor Fitzgerald I-MAB price target raised to $55 from $50 at Cantor Fitzgerald 09 Feb 13 Jan IMAB I-MAB $59.12 / -4.98 (-7.77%) 09/04/20 Fly Intel: Wall Street's top stories for Friday 09/04/20 Fly Intel: Wall Street's top stories at midday
Periodicals	Apple could launch foldable iPhone as soon as 2023, Business Insider reports » 06:12 03/03/21 03/03 06:12 03/03/21 06:12 AAPL Apple $125.17 / -2.6 (-2.03%) A foldable iPhone could… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AAPL Apple $125.17 / -2.6 (-2.03%) 03/02/21 Target to open approx. 100 Ulta Beauty at Target shop-in-shops in 2021 02/25/21 Target announces enhanced Apple shopping experience for customers 02/19/21 Luminar, Velodyne Lidar move up after Bloomberg says Apple looking at LiDAR 02/19/21 Energous jumps 53% on Bloomberg report that Apple is working on battery pack AAPL Apple $125.17 / -2.6 (-2.03%) 03/01/21 Wedbush Asia checks bullish for Apple iPhone 12 builds, says Wedbush 03/01/21 JPMorgan Broadcom won new new wireless charging chipset in iPhone 13, says JPMorgan 02/25/21 JPMorgan JPMorgan 'tweaks' EPS estimate for Apple after cut to iPhone forecasts 02/24/21 Piper Sandler Piper sees Apple developing 'full-blown' branded electric vehicle AAPL Apple $125.17 / -2.6 (-2.03%) 01/27/21 Apple reports Q1 EPS $1.70, consensus $1.41 01/27/21 Notable companies reporting after market close 10/29/20 Apple says Q4 results were ahead of expectations 10/29/20 Apple reports Q4 Services revenue $14.55B vs. $12.51B last year AAPL Apple $125.17 / -2.6 (-2.03%) 03/02/21 New Apple Card users get 6% Daily Cash on Apple purchases, 9to5Mac says 03/01/21 New EU 'Right to Repair' rules require goods to be repairable, Independent says 03/01/21 All Apple stores in U.S. open for first time since pandemic, CNBC reports 02/24/21 Biden to address chip shortages with executive action, WSJ reports AAPL Apple $125.17 / -2.6 (-2.03%) 03/02/21 Fly Intel: Wall Street's top stories for Tuesday 02/27/21 Charged: Tesla temporarily halts Model 3 line at CA plant 02/25/21 Analysts cut Verizon, AT&T ratings after companies spend big in FCC auction 02/20/21 Charged: Analyst sees Apple announcing EV partnership in 2021 03/17/21 Technology AAPL Apple $125.17 / -2.6 (-2.03%) 03/02/21 Notable open interest changes for March 2nd 03/02/21 Apple call buyer realizes 91% same-day gains 03/01/21 Notable open interest changes for March 1st 02/26/21 Notable open interest changes for February 26th

Hot Stocks	Dycom announces new $150M share repurchase plan » 06:11 03/03/21 03/03 06:11 03/03/21 06:11 DY Dycom $77.36 / -3.6 (-4.45%) Dycom announced that its… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events DY Dycom $77.36 / -3.6 (-4.45%) 01/15/21 Dycom COO sells 52K shares of common stock 12/16/20 Dycom COO sells 150.1K shares of common stock 11/24/20 Dycom falls -17.3% 11/24/20 Dycom falls -15.6% DY Dycom $77.36 / -3.6 (-4.45%) 01/27/21 KeyBanc Dycom upgraded to Overweight at KeyBanc 01/27/21 KeyBanc Dycom upgraded to Overweight from Sector Weight at KeyBanc 01/07/21 B. Riley Securities Dycom price target raised to $97 from $92 at B. Riley Securities 11/25/20 DA Davidson Dycom price target raised to $80 from $60 at DA Davidson DY Dycom $77.36 / -3.6 (-4.45%) 06:06 Today Dycom sees Q1 revenue in-line to modestly lower than Q4, consensus $786.14M 06:04 Today Dycom reports Q4 EPS (7c), consensus 4c 11/24/20 Dycom sees modestly lower contract revenues in Q4, consensus $744.13M 11/24/20 Dycom reports Q3 adj. EPS $1.06, consensus $1.05 09:00 Today Dycom - DY 03/31/21 Dycom
Recommendations	Amyris price target raised to $35 from $11 at H.C. Wainwright » 06:11 03/03/21 03/03 06:11 03/03/21 06:11 AMRS Amyris $19.91 / +4.29 (+27.46%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options AMRS Amyris $19.91 / +4.29 (+27.46%) 03/01/21 Amyris to acquire Costa Brazil brand, terms not disclosed 02/24/21 Amyris launches Pipette clean baby care brand in Target 02/22/21 Amyris announces pre-clinical results for COVID RNA vaccine platform 02/02/21 Amyris announces results from clinical study of clean topical formulation AMRS Amyris $19.91 / +4.29 (+27.46%) 02/26/21 Fly Intel: Top five analyst initiations 02/26/21 Roth Capital Amyris initiated with a Buy at Roth Capital 01/06/21 Cowen Amyris upgraded to Outperform with $9 price target at Cowen 01/06/21 Cowen Amyris upgraded to Outperform from Market Perform at Cowen AMRS Amyris $19.91 / +4.29 (+27.46%) 03/02/21 Amyris sees FY21 revenue $400M, consensus $231.77M 03/02/21 Amyris reports Q4 adjusted EPS (3c), consensus (9c) AMRS Amyris $19.91 / +4.29 (+27.46%) 03/02/21 Fly Intel: Wall Street's top stories at midday 09/15/20 Fly Intel: Wall Street's top stories for Tuesday 09/15/20 Fly Intel: Wall Street's top stories at midday 09/11/20 Fly Intel: Wall Street's top stories for Friday 03/02/21 41st Annual Healthcare Virtual Conference 03/15/21 33rd Annual Roth Virtual Conference AMRS Amyris $19.91 / +4.29 (+27.46%) 01/04/21 Amyris call volume above normal and directionally bullish 12/30/20 Amyris call volume above normal and directionally bullish 12/28/20 Amyris call volume above normal and directionally bullish 12/24/20 Unusual call flow in option market yesterday
Hot Stocks	Mack-Cali Realty names Mahbod Nia CEO » 06:10 03/03/21 03/03 06:10 03/03/21 06:10 CLI Mack-Cali Realty $14.24 / +0.11 (+0.78%) , NRE Northstar Realty Europe $17.02 / + (+0.00%) Mack-Cali Realty (CLI)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CLI CLI Mack-Cali Realty $14.24 / +0.11 (+0.78%) 01/06/21 Mack-Cali Realty sells Riverwatch Commons, Crystal House Apartments 12/03/20 Mack-Cali Realty announces $61M sale of NJ property 11/23/20 Mack-Cali Realty sells Parsippany, NJ property to Birch Group for $12.75M. 09/30/20 Mack-Cali Realty suspends dividend for Q3, Q4 CLI NRE CLI Mack-Cali Realty $14.24 / +0.11 (+0.78%) 12/10/20 Citi Citi opens '90-day negative Catalyst Watch' on Mack-Cali Realty 08/04/20 Fly Intel: Top five analyst downgrades 08/04/20 Deutsche Bank Mack-Cali Realty downgraded to Hold from Buy at Deutsche Bank 07/20/20 Deutsche Bank Mack-Cali Realty price target lowered to $20 from $22 at Deutsche Bank NRE Northstar Realty Europe $17.02 / + (+0.00%) CLI CLI Mack-Cali Realty $14.24 / +0.11 (+0.78%) 02/25/21 Mack-Cali Realty sees Q1 FFO 12c-15c, one estimate 27c 02/25/21 Mack-Cali Realty reports Q4 FFO 16c, consensus 24c 11/04/20 Mack-Cali Realty reports Q3 core FFO 30c, consensus 29c
Downgrade	Kopin downgraded to Neutral from Buy at H.C. Wainwright » 06:09 03/03/21 03/03 06:09 03/03/21 06:09 KOPN Kopin $9.92 / +0.78 (+8.53%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options KOPN Kopin $9.92 / +0.78 (+8.53%) 02/23/21 Kopin director Collins sells almost $2M in company shares 02/23/21 Kopin trading resumes 02/23/21 Kopin trading halted, volatility trading pause 02/02/21 Kopin, HMDmd in development pact for wearable display system for surgeons KOPN Kopin $9.92 / +0.78 (+8.53%) 01/11/21 H.C. Wainwright Kopin price target raised to $3.50 from $2 at H.C. Wainwright 08/25/20 Fly Intel: Top five analyst initiations 08/25/20 H.C. Wainwright Kopin initiated with a Buy at H.C. Wainwright 08/05/20 Ladenburg Kopin price target raised to $2.50 from $1.50 at Ladenburg KOPN Kopin $9.92 / +0.78 (+8.53%) 11/03/20 Kopin reports Q3 EPS (1c), consensus (2c) KOPN Kopin $9.92 / +0.78 (+8.53%) 03/02/21 Unusually active option classes on open March 2nd
Periodicals	JPMorgan looks to sublet office space at two NYC towers, Bloomberg reports » 06:08 03/03/21 03/03 06:08 03/03/21 06:08 JPM JPMorgan $150.01 / -0.4698 (-0.31%) JPMorgan Chase is looking… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events JPM JPMorgan $150.01 / -0.4698 (-0.31%) 03/02/21 Domtar enters into an ASR with JPMorgan to repurchase $200M of its common stock 02/18/21 Verisk Analytics appoints Kathy Card Beckles as general counsel 02/16/21 Berkshire Hathaway buys Verizon, exits Barrick Gold in Q4 02/16/21 Buffett's Berkshire Hathaway reports no longer holding JPMorgan JPM JPMorgan $150.01 / -0.4698 (-0.31%) 01/19/21 DA Davidson JPMorgan price target raised to $163 from $147 at DA Davidson 01/19/21 Seaport Global JPMorgan price target raised to $157 from $140 at Seaport Global 01/19/21 RBC Capital JPMorgan price target raised to $150 from $130 at RBC Capital 01/19/21 Credit Suisse JPMorgan price target raised to $150 from $142 at Credit Suisse JPM JPMorgan $150.01 / -0.4698 (-0.31%) 01/15/21 JPMorgan reports Q4 EPS $3.79, consensus $2.62 01/14/21 Notable companies reporting before tomorrow's open 01/14/21 Notable companies reporting before tomorrow's open 01/14/21 Fly Intel: What to watch in first round of big bank earnings reports JPM JPMorgan $150.01 / -0.4698 (-0.31%) 02/26/21 BofA, JPMorgan give U.S. employees PTO for COVID-19 vaccinations, Reuters says 02/22/21 Toast planning IPO that could value it at around $20B, WSJ reports 02/10/21 Two JPMorgan activism defense bankers leave company, Reuters says 01/27/21 U.K. taps HSBC, JPMorgan to advise on first 'green' bond, Reuters says JPM JPMorgan $150.01 / -0.4698 (-0.31%) 01/15/21 Fly Intel: Wall Street's top stories for Friday 01/15/21 Fly Intel: Wall Street's top stories at midday 01/15/21 Fly Intel: Pre-market Movers 01/04/21 Fly Intel: Wall Street's top stories for Monday 03/02/21 15th Annual Capital Link International Shipping Virtual Forum 04/14/21 JPMorgan - JPM

Upgrade	Farmers National Banc upgraded to Overweight from Neutral at Piper Sandler » 06:07 03/03/21 03/03 06:07 03/03/21 06:07 FMNB Farmers National Banc $14.34 / +0.065 (+0.46%) Piper Sandler analyst R.… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Earnings FMNB Farmers National Banc $14.34 / +0.065 (+0.46%) 09/24/20 Boenning & Scattergood Farmers National Banc resumed with an Outperform at Boenning & Scattergood 06/17/20 Raymond James Farmers National Banc upgraded to Outperform from Market Perform at Raymond James 06/17/20 Raymond James Farmers National Banc upgraded to Outperform from Market Perform at Raymond James 05/04/20 Raymond James Farmers National Banc downgraded at Raymond James on valuation FMNB Farmers National Banc $14.34 / +0.065 (+0.46%) 01/28/21 Farmers National Banc reports Q4 EPS 45c, consensus 33c 10/28/20 Farmers National Banc reports Q3 EPS 38c, consensus 32c
Downgrade	KeyCorp downgraded to Neutral from Overweight at Piper Sandler » 06:06 03/03/21 03/03 06:06 03/03/21 06:06 KEY KeyCorp $20.65 / -0.09 (-0.43%) Piper Sandler analyst R.… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events KEY KeyCorp $20.65 / -0.09 (-0.43%) 01/26/21 KeyCorp rises -0.9% 01/26/21 KeyCorp rises 0.2% 01/21/21 KeyCorp sees long-term ROTCE 16%-19%, cash efficiency ratio 54%-56% 01/21/21 KeyCorp sees FY21 NII relatively stable, including ongoing PPP participation KEY KeyCorp $20.65 / -0.09 (-0.43%) 02/17/21 Citi Citi recommends two new U.S. bank pair trades 01/06/21 Deutsche Bank KeyCorp price target raised to $18 from $14 at Deutsche Bank 01/04/21 Barclays KeyCorp price target raised to $20 from $15 at Barclays 10/26/20 Fly Intel: Top five analyst downgrades KEY KeyCorp $20.65 / -0.09 (-0.43%) 01/21/21 KeyCorp reports Q4 EPS 56c, consensus 43c 10/21/20 KeyCorp reports Q3 EPS 41c, consensus 37c 10/20/20 Notable companies reporting before tomorrow's open 10/20/20 Notable companies reporting before tomorrow's open KEY KeyCorp $20.65 / -0.09 (-0.43%) 01/20/21 Notable companies reporting before tomorrow's open 01/20/21 Notable companies reporting before tomorrow's open KEY KeyCorp $20.65 / -0.09 (-0.43%) 01/21/21 Fly Intel: Pre-market Movers 10/26/20 Apple coverage reinstatement, KeyCorp downgrade among top calls on Wall Street 04/20/21 KeyCorp - KEY
Downgrade	First Financial Bancorp downgraded to Neutral from Overweight at Piper Sandler » 06:06 03/03/21 03/03 06:06 03/03/21 06:06 FFBC First Financial Bancorp $22.73 / -0.21 (-0.92%) Piper Sandler analyst R.… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly FFBC First Financial Bancorp $22.73 / -0.21 (-0.92%) 12/22/20 First Financial Bancorp announces stock repurchase plan FFBC First Financial Bancorp $22.73 / -0.21 (-0.92%) 02/01/21 Piper Sandler First Financial Bancorp upgraded to Overweight from Neutral at Piper Sandler FFBC First Financial Bancorp $22.73 / -0.21 (-0.92%) 01/28/21 First Financial Bancorp reports Q4 adjusted EPS 51c, consensus 46c 10/22/20 First Financial Bancorp reports Q3 adjusted EPS 44c, consensus 37c FFBC First Financial Bancorp $22.73 / -0.21 (-0.92%) 10/22/20 Fly Intel: After-Hours Movers
Earnings	Dycom sees Q1 revenue in-line to modestly lower than Q4, consensus $786.14M » 06:06 03/03/21 03/03 06:06 03/03/21 06:06 DY Dycom $77.36 / -3.6 (-4.45%) Sees Q1 adjusted EBITDA… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events DY Dycom $77.36 / -3.6 (-4.45%) 01/15/21 Dycom COO sells 52K shares of common stock 12/16/20 Dycom COO sells 150.1K shares of common stock 11/24/20 Dycom falls -17.3% 11/24/20 Dycom falls -15.6% DY Dycom $77.36 / -3.6 (-4.45%) 01/27/21 KeyBanc Dycom upgraded to Overweight at KeyBanc 01/27/21 KeyBanc Dycom upgraded to Overweight from Sector Weight at KeyBanc 01/07/21 B. Riley Securities Dycom price target raised to $97 from $92 at B. Riley Securities 11/25/20 DA Davidson Dycom price target raised to $80 from $60 at DA Davidson DY Dycom $77.36 / -3.6 (-4.45%) 06:04 Today Dycom reports Q4 EPS (7c), consensus 4c 11/24/20 Dycom sees modestly lower contract revenues in Q4, consensus $744.13M 11/24/20 Dycom reports Q3 adj. EPS $1.06, consensus $1.05 09:00 Today Dycom - DY 03/31/21 Dycom
Earnings	National Vision sees FY21 adjusted EPS 88c-93c, consensus 88c » 06:04 03/03/21 03/03 06:04 03/03/21 06:04 EYE National Vision $47.60 / -1.79 (-3.62%) Sees FY21 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Earnings On The Fly Events EYE National Vision $47.60 / -1.79 (-3.62%) 01/11/21 Loop Capital National Vision downgraded to Hold from Buy at Loop Capital on valuation 01/11/21 Loop Capital National Vision downgraded to Hold from Buy at Loop Capital 01/11/21 Loop Capital National Vision downgraded to Hold from Buy at Loop Capital 11/18/20 Berenberg National Vision downgraded to Hold from Buy at Berenberg EYE National Vision $47.60 / -1.79 (-3.62%) 06:02 Today National Vision reports Q4 adjusted EPS 45c, consensus 13c 11/05/20 National Vision sees FY20 adjusted EPS 53c-57c, consensus 23c 11/05/20 National Vision sees Q4 adjusted EPS 10c-14c, consensus 12c 11/05/20 National Vision reports Q3 adjusted EPS 54c, consensus 27c EYE National Vision $47.60 / -1.79 (-3.62%) 12/10/20 Goldman Sachs says buy Floor & Decor, sell Best Buy 10:00 Today National Vision - EYE

Earnings	Dycom reports Q4 EPS (7c), consensus 4c » 06:04 03/03/21 03/03 06:04 03/03/21 06:04 DY Dycom $77.36 / -3.6 (-4.45%) Reports Q4 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events DY Dycom $77.36 / -3.6 (-4.45%) 01/15/21 Dycom COO sells 52K shares of common stock 12/16/20 Dycom COO sells 150.1K shares of common stock 11/24/20 Dycom falls -17.3% 11/24/20 Dycom falls -15.6% DY Dycom $77.36 / -3.6 (-4.45%) 01/27/21 KeyBanc Dycom upgraded to Overweight at KeyBanc 01/27/21 KeyBanc Dycom upgraded to Overweight from Sector Weight at KeyBanc 01/07/21 B. Riley Securities Dycom price target raised to $97 from $92 at B. Riley Securities 11/25/20 DA Davidson Dycom price target raised to $80 from $60 at DA Davidson DY Dycom $77.36 / -3.6 (-4.45%) 11/24/20 Dycom sees modestly lower contract revenues in Q4, consensus $744.13M 11/24/20 Dycom reports Q3 adj. EPS $1.06, consensus $1.05 09:00 Today Dycom - DY 03/31/21 Dycom
Upgrade	Rapid7 upgraded to Overweight with $100 target at Piper Sandler » 06:04 03/03/21 03/03 06:04 03/03/21 06:04 RPD Rapid7 $79.21 / -2.07 (-2.55%) Piper Sandler analyst Rob… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events RPD Rapid7 $79.21 / -2.07 (-2.55%) 02/01/21 Rapid7 acquires Kubernetes security provider Alcide for $50M 12/17/20 Rapid7 partners with SCADAfence to provide visibility into OT assets 12/16/20 Rapid7 director sells 20.2K shares of common stock 10/30/20 Rapid7 and Snyk plan to deepen strategic partnership RPD Rapid7 $79.21 / -2.07 (-2.55%) 03/02/21 Piper Sandler Rapid7 upgraded to Overweight from Neutral at Piper Sandler 02/17/21 Stifel Rapid7 resumed with a Buy at Stifel 02/10/21 Morgan Stanley Morgan Stanley downgrades Qualys to Underweight on growth and margin pressures 02/10/21 RBC Capital Rapid7 price target raised to $110 from $105 at RBC Capital RPD Rapid7 $79.21 / -2.07 (-2.55%) 02/09/21 Rapid7 sees FY21 EPS (3c)-(4c), consensus 15c 02/09/21 Rapid7 sees Q1 EPS (8c)-(6c), consensus (4c) 02/09/21 Rapid7 reports Q4 EPS (7c), consensus (8c) 11/04/20 Rapid7 sees Q4 EPS (9c)-(7c), consensus (4c) RPD Rapid7 $79.21 / -2.07 (-2.55%) 02/18/21 Wells Fargo, Seagate upgrades among today's top calls on Wall Street 12/21/20 Analysts move to sidelines on SolarWinds following cyberattack 03/10/21 Rapid7, Inc.
Earnings	National Vision reports Q4 adjusted EPS 45c, consensus 13c » 06:02 03/03/21 03/03 06:02 03/03/21 06:02 EYE National Vision $47.60 / -1.79 (-3.62%) Reports Q4 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings On The Fly Events EYE National Vision $47.60 / -1.79 (-3.62%) 01/11/21 Loop Capital National Vision downgraded to Hold from Buy at Loop Capital on valuation 01/11/21 Loop Capital National Vision downgraded to Hold from Buy at Loop Capital 01/11/21 Loop Capital National Vision downgraded to Hold from Buy at Loop Capital 11/18/20 Berenberg National Vision downgraded to Hold from Buy at Berenberg EYE National Vision $47.60 / -1.79 (-3.62%) 11/05/20 National Vision sees FY20 adjusted EPS 53c-57c, consensus 23c 11/05/20 National Vision sees Q4 adjusted EPS 10c-14c, consensus 12c 11/05/20 National Vision reports Q3 adjusted EPS 54c, consensus 27c EYE National Vision $47.60 / -1.79 (-3.62%) 12/10/20 Goldman Sachs says buy Floor & Decor, sell Best Buy 10:00 Today National Vision - EYE
Upgrade	CIBC upgraded to Neutral from Underperform at Credit Suisse » 06:02 03/03/21 03/03 06:02 03/03/21 06:02 CM CIBC $94.91 / +1.43 (+1.53%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CM CIBC $94.91 / +1.43 (+1.53%) 02/03/21 CIBC says sale of majority stake in FirstCaribbean will not proceed 12/03/20 CIBC appoints Katharine Stevenson as chair of the board CM CIBC $94.91 / +1.43 (+1.53%) 03/01/21 Desjardins CIBC price target raised to C$122 from C$117 at Desjardins 02/26/21 Canaccord CIBC price target raised to C$131 from C$124.50 at Canaccord 02/26/21 RBC Capital CIBC price target raised to C$141 from C$130 at RBC Capital 02/26/21 National Bank CIBC price target raised to C$130 from C$126 at National Bank CM CIBC $94.91 / +1.43 (+1.53%) 12/03/20 CIBC reports Q4 adjusted EPS C$2.79 vs. C$2.84 last year
Hot Stocks	CMC Materials raises quarterly dividend to 46c, raises share repurchase to $150M » 06:02 03/03/21 03/03 06:02 03/03/21 06:02 CCMP CMC Materials $168.26 / -8.41 (-4.76%) CMC Materials announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events CCMP CMC Materials $168.26 / -8.41 (-4.76%) 03/01/21 CMC Materials to acquire International Test Solutions for about $125M in cash 10/01/20 Cabot Microelectronics announces name change to CMC Materials CCMP CMC Materials $168.26 / -8.41 (-4.76%) 01/25/21 Citi Citi moves Marvell up to pick in semiconductor equipment 01/25/21 Citi CMC Materials price target raised to $150 from $140 at Citi 01/18/21 Goldman Sachs CMC Materials upgraded to Neutral from Sell at Goldman Sachs 11/13/20 Fly Intel: Top five analyst downgrades CCMP CMC Materials $168.26 / -8.41 (-4.76%) 02/03/21 CMC Materials raises FY21 adjusted EBITDA view to $367M-$387M 02/03/21 CMC Materials sees Q2 revenue up low single digits from Q1 02/03/21 CMC Materials reports Q1 adjusted EPS $1.92, consensus $1.73 11/11/20 CMC Materials sees FY21 adjusted EBITDA $358M-$385M 03/11/21 Specialty Chemicals Virtual Conference 03/11/21 2021 Consumer, Industrials, & TMT Investor Virtual Conference 09:00 Today CMC Materials Inc

Events

Earnings calls, analyst events, roadshows and more

PUK
Today at 06:30

Prudential plc - PUK Conference Calls
Today at 07:00

MBA Mortgage Applications: Refinance Index W/W: 2/26/2021 Government Event
Today at 07:00

MBA Mortgage Applications: Composite Index W/W: 2/26/2021 Government Event
Today at 07:00

MBA Mortgage Applications: Purchase Index W/W: 2/26/2021 Government Event
TSHA
Today at 08:00

Taysha Gene Therapies - TSHA Conference Calls
OPTN
Today at 08:00

Optinose - OPTN Conference Calls
BQ
Today at 08:00

Boqii - BQ Conference Calls
ISEE
Today at 08:00

Iveric bio - ISEE Conference Calls
Today at 08:15

ADP Employment Report: Private Payrolls M/M: February 2021 Government Event
WEN
Today at 08:30

Wendy's - WEN Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	SWTX X SWTX SpringsWorks Therapeutics Block Trade Managers: Morgan Stanley Priced at: $84.00 1.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRT X VRT Vertiv Holdings Block Trade Managers: JPMorgan Priced at: $20.70 17.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan Priced at: $120.00 2.08M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYNH X SYNH Syneos Health Secondary Managers: Goldman Sachs Priced at: $74.95 7M Shares EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $11.88 30M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FRC X FRC First Republic Spot Secondary Managers: BofA, JPMorgan & Morgan Stanley Priced at: $166.50 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HLNE X HLNE Hamilton Lane Spot Secondary Managers: JPMorgan Priced at: $88.25 1.45M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial JELD X JELD Jeld-Wen Spot Secondary Managers: Goldman Sachs Priced at: $29.25 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCL X RCL Royal Caribbean Spot Secondary Managers: Morgan Stanley Priced at: $91.00 16.938M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SITC X SITC Site Centers Spot Secondary Managers: Morgan Stanley & Wells Fargo Priced at: $13.20 15M Shares WSC X WSC WillScot Mobile Mini Spot Secondary Managers: Morgan Stanley Priced at: $27.20 12.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	INDT X INDT Indus Realty Trust Secondary Managers: Morgan Stanley, Citi & Baird, BTIG, JMP Securities, JPMorgan Priced at: $60.00 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MORF X MORF Morphic Secondary Managers: Jefferies, Cowen, BMO Capital & RBC Capital Priced at: $70.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MGY X MGY Magnolia Oil & Gas Spot Secondary Managers: Credit Suisse & Citi Priced at: $10.50 17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.55 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RDHL X RDHL RedHill Biopharma Spot Secondary Managers: H.C. Wainwright Priced at: $8.00 4.375M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	GROY X GROY Gold Royalty IPO Managers: H.C. Wainwright & BMO Capital, CIBC, HAYW, Raymond James, Roth Capital, Scotiabank, Sprott, TD Securities $5.00 16M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial OSCR X OSCR Oscar Health IPO Managers: Goldman Sachs, Morgan Stanley & Allen & Co., Wells Fargo, Credit Suisse, BofA, Cowen, LION, Ramirez, SIEB $36.00-38.00 31M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASLN X ASLN Aslan Pharmaceuticals Secondary Managers: Jefferies & Piper Sandler $5.25 Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDLX X CDLX Cardlytics Secondary Managers: BofA, JPMorgan, Wells Fargo & Raymond James $141.28 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HSKA X HSKA Heska Secondary Managers: JPMorgan & Piper Sandler $201.39 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ICAD X ICAD iCAD Spot Secondary Managers: Guggenheim $18.00-18.25 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PLXP X PLXP PLx Pharma Spot Secondary Managers: Raymond James & Oppenheimer $9.14 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SSYS X SSYS Stratasys Spot Secondary Managers: JPMorgan & Stifel $29.00-30.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	INNV X INNV InnovAge IPO Managers: JPMorgan, Barclays, Goldman Sachs & Citi, Baird, William Blair, Piper Sandler, Capital One, Loop Capital, SIEB, Roberts & Ryans $17.00-19.00 16.667M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AMRK X AMRK A-Mark Precious Metals Secondary Managers: DA Davidson & Roth Capital, CIBC $27.97 2.5M Shares COHU X COHU Cohu Secondary Managers: Citi, Goldman Sachs & Stifel, B. Riley Securities, Craig-Hallum, DA Davidson $45.99 4.5M Shares DGII X DGII Digi International Secondary Managers: Piper Sandler $23.46 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FVRR X FVRR Fiverr Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley $279.44 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SLQT X SLQT SelectQuote Secondary Managers: Credit Suisse, Morgan Stanley, Goldman Sachs, RBC Capital, Barclays, Citi, Evercore ISI & Jefferies, Cantor Fitzgerald, Keefe Bruyette, Piper Sandler, Drexel Hamilton $32.22 10.6M Shares
Thurs	NRIX X NRIX Nurix Therapeutics Secondary Managers: JPMorgan, Piper Sandler & Stifel, RBC Capital, Needham $35.91 4M Shares
Fri	No deals

View All Syndicate Announcements »

GlycoMimetics reports Q1 EPS (18c), consensus (30c)

TODAY'S FREE FLY STORIES

Get Full Fly Access